QRG Capital Management Inc. Acquires 50,247 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

QRG Capital Management Inc. raised its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 53.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 143,747 shares of the company’s stock after acquiring an additional 50,247 shares during the quarter. QRG Capital Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $2,028,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wellington Management Group LLP boosted its position in shares of Teva Pharmaceutical Industries by 42.2% during the third quarter. Wellington Management Group LLP now owns 344,587 shares of the company’s stock worth $3,515,000 after purchasing an additional 102,261 shares in the last quarter. Nordea Investment Management AB boosted its position in shares of Teva Pharmaceutical Industries by 1.7% during the fourth quarter. Nordea Investment Management AB now owns 89,136 shares of the company’s stock worth $931,000 after purchasing an additional 1,521 shares in the last quarter. Gateway Investment Advisers LLC boosted its position in shares of Teva Pharmaceutical Industries by 28.6% during the fourth quarter. Gateway Investment Advisers LLC now owns 41,882 shares of the company’s stock worth $437,000 after purchasing an additional 9,312 shares in the last quarter. SG Americas Securities LLC lifted its position in Teva Pharmaceutical Industries by 31.7% in the 4th quarter. SG Americas Securities LLC now owns 544,878 shares of the company’s stock valued at $5,689,000 after acquiring an additional 131,043 shares in the last quarter. Finally, AustralianSuper Pty Ltd lifted its position in Teva Pharmaceutical Industries by 18.8% in the 4th quarter. AustralianSuper Pty Ltd now owns 9,039,070 shares of the company’s stock valued at $94,368,000 after acquiring an additional 1,431,671 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Insider Transactions at Teva Pharmaceutical Industries

In related news, insider Vikki L. Conway sold 15,219 shares of Teva Pharmaceutical Industries stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 15,500 shares of the business’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total value of $260,400.00. Following the completion of the sale, the chief accounting officer now owns 17,814 shares of the company’s stock, valued at approximately $299,275.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Vikki L. Conway sold 15,219 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $16.74, for a total transaction of $254,766.06. The disclosure for this sale can be found here. Insiders have sold 549,719 shares of company stock worth $9,353,736 in the last ninety days. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock traded down $0.43 during trading on Tuesday, hitting $16.65. 8,413,416 shares of the stock were exchanged, compared to its average volume of 10,367,912. The stock has a market capitalization of $18.86 billion, a price-to-earnings ratio of -41.95, a price-to-earnings-growth ratio of 1.64 and a beta of 0.90. The company has a fifty day moving average price of $16.60 and a 200-day moving average price of $14.15. Teva Pharmaceutical Industries Limited has a 1-year low of $7.95 and a 1-year high of $17.69. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.20.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, May 8th. The company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.03). The firm had revenue of $3.82 billion for the quarter, compared to analyst estimates of $3.70 billion. Teva Pharmaceutical Industries had a positive return on equity of 37.33% and a negative net margin of 2.88%. As a group, equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on TEVA shares. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, May 30th. Barclays boosted their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, June 5th. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, July 10th. StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 20th. Finally, Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Wednesday, July 10th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average price target of $18.56.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.